CollPlant Biotechnologies Ltd(OPHI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -9.38 | Insider Own | 17.54% | Shs Outstand | 1.9M | Perf Week | -14.25% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.6M | Perf Month | -13.54% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 10.24% | Short Float | 2.28% | Perf Quarter | 4.06% |
| Income | -0.01B | P/S | 18.49 | EPS this Y | - | Inst Trans | 1.71% | Short Ratio | 0.09 | Perf Half Y | -26.59% |
| Sales | 0.00B | P/B | 1.54 | EPS next 5Y | - | ROA | -101.59% | Short Interest | 0.04M | Perf YTD | -77.64% |
| Book/sh | 2.04 | P/C | 2.01 | EPS past 3/5Y | 15.02% -2.35% | ROE | -161.98% | 52W High | -86.09% ($22.50) | Perf Year | -85.37% |
| Cash/sh | 1.56 | P/FCF | - | Sales past 3/5Y | 99.41% -17.32% | ROIC | -265.61% | 52W Low | 18.7% ($2.64) | Perf 3Y | -94.39% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.63% | Gross Margin | -587.74% | Volatility(W/M) | 16.25% 11.99% | Perf 5Y | -98.35% |
| Dividend TTM | - | EV/Sales | 17.58 | Sales Y/Y TTM | -86.76% | Oper. Margin | -3900.94% | ATR (14) | 0.49 | Perf 10Y | -98.25% |
| Dividend Ex-Date | - | Quick Ratio | 1.35 | EPS Q/Q | 33.15% | Profit Margin | -3934.91% | RSI (14) | 40.76 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.57 | Sales Q/Q | -39.66% | SMA20 | -19.26% ($3.88) | Beta | 0.65 | Target Price | $120 |
| Payout | - | Debt/Eq | 0.9 | Earnings | 2026/9/30 | SMA50 | -18.17% ($3.83) | Rel Volume | 0.12 | Prev Close | $3.21 |
| Employees | 39 | LT Debt/Eq | 0.6 | EPS/Sales Surpr. | - | SMA200 | -24.69% ($4.16) | Avg Volume(3M) | 0.38M | Price | $3.13 |
| IPO | 2015/5/21 | Option/Short | No/Yes | Trades | 204 | Volume | 45,280 | Change | -2.49% |
💡 An Israeli biotech company with plant-derived recombinant human collagen technology. It recently acquired the Israeli optical computing company LightSolver, shifting its business focus toward the development of laser-based computing devices, and is undergoing a process to change its name to Optify Computing and update its Nasdaq ticker from the existing CLGN. It will continue to hold its collagen and bio-ink assets.
Over the past 1 year, on the lower side
86% below its 1-year high.
Traded less than usual. That is 12% of its average volume.
OPHI has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,849. Peers typically go for $596.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.3%. The S&P 500 did +47% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 10.2%.
Tap to view numbers
It ranks #525 of 598 in the industry
Based on market cap of $6M.
FAQ
OPHI belongs to the Healthcare sector and operates in the Biotechnology industry.
The market cap of OPHI is approximately $6M, ranking 5,499 within its sector.
OPHI has recorded a 52-week high of $22.50 and a low of $2.64.